PPD, Schrödinger, Beam set terms for IPO; FDA expands use of Merck's Dificid
→ With slower rates of patient enrollment than expected for their Phase III trial of its PARP inhibitor pamiparib vs placebo — as a therapy in patients with inoperable locally advanced or metastatic gastric cancer who have responded to platinum-based first line chemotherapy — BeiGene is converting the trial to a Phase II. Patient enrollment began in July 2018 and the company has thus far registered approximately 120 patients globally.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.